Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...
When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...
PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial. This is an ASCO Meeting Abstract from the 2025 ASCO ...
An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...
When the PSA is elevated: for which men is a biopsy necessary to confirm or rule out suspected prostate cancer? In a retrospective study, scientists from the German Cancer Research Center (DKFZ) and ...
MRI should be considered an adjunct to, and not a replacement for, biopsies for men on active surveillance for prostate cancer. MRI does not consistently rule out the presence of Gleason grade group 2 ...
A recent Radiology journal study assesses the power of a fully automated deep learning (DL) model to produce deterministic outputs for identifying clinically significant prostate cancer (csPCa). Study ...
Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results